An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split. Shares of ONTX can be purchased through any online brokerage account. I'm starting to get suspicious about this ONTX outfit? r/ONTX: Onconova Therapeutics (ONTX) Discussion Board. Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Phase 2 in Austria and England. Onconova Therapeutics prices $2.5 mln stock offering at $2.10 a share. The offer price represents an almost 17% discount at . Changes in short volume can be used to identify positive and negative investor sentiment. Immunic (NASDAQ:IMUX) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the better stock?We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking. 21, 2017 at 9:44 a.m. The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) - a biopharmaceutical company focused on discovering and developing novel products to treat cancer - as of 11:17 PM ET. View Onconova Therapeutics' Short Interest. Looking for new stock ideas? The bears made the stock sink to a new 52-week low. Conference call and live webcast at 4:30 p.m. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutics Inc (NASDAQ: ONTX) has priced an underwritten public offering of 5 million shares at .20 for gross proceeds of million. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Announces Pricing of $21 Million Public Offering of Common Stock. To all those who lost money on this scam: You can make some of your money back by shorting it right now (if you can find stock to borrow). Only 1.00% of the stock of Onconova Therapeutics is held by insiders. Expect a press release at the end of day. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. Volume has increased on the last day by 60 thousand shares but on . Identify stocks that meet your criteria using seven unique stock screeners. View as data table, Onconova Therapeutics, Inc. price and volume. The chart has 1 X axis displaying Time. Onconova Therapeutics, Inc. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. This means that the latest group of novice investors that Guggenheim conned will be diluted to near zero in record time. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Announces Pricing of $21 Million Public Offering of Common Stock. 09/22/21 08:08:07 AM. In a press release yesterday, Onconova Therapeutics announced that it had completed a fund raise with gross proceeds of $28.75 million at $1 per share . Onconova Therapeutics is a clinical-stage biopharma company that's focused on developing products for cancer care. The number of messages related to AMC on trading-focused social media site Stocktwits rose more than 7% on Wednesday, with most of them reflecting a positive sentiment. View Onconova Therapeutics' earnings history. You need to be a logged in subscriber to view this content. Onconova is focused on discovering and developing novel products for patients with cancer. Onconova Therapeutics saw a drop in short interest in November. Fundamental company data provided by Zacks Investment Research. SRNE 5.94 0.03 (0.50%) Post-Market 0.00 (0.00%) 70,503. By David Moadel, InvestorPlace . View analyst ratings for Onconova Therapeutics or view top-rated stocks. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB - Research Report), Onconova Therapeutics (ONTX - Research Report) and Personalis (PSNL - Research Report).Biogen (BIIB) In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Biogen, with a price target of $452.00. NEWTOWN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), todayannouncedthat Dr. Steven M. Fruchtman, . Onconova Therapeutics, Inc. ( ONTX ), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 5,000,000 . 2 brokers have issued 1 year price objectives for Onconova Therapeutics' stock. Adira. TVIX is a guarantee because of the inevitable degradation of the contracts and ONTX is a sure short bet because of the utter corruption of the management and the board. View which stocks are hot on social media with MarketBeat's trending stocks report. 52wk Low 0.93. I really thought it will be at least Christmas before $1 is reached and Fruchtman does his reverse split scam again. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 52wk Low 0.29. US electric vehicle charging network strategy being released, Satellite images, expert suggest Iranian space launch coming, The Trade Desk Stock Deserves a Second Look, 3 Dependable Dow Stocks to Buy in December, MarketBeat: Week in Review 12-6 – 12/10, Reasons to Invest in (or Steer Clear of) Real Estate in 2022, GameStop Reports Q3 Earnings, And It’s A Mixed Bag, Arhaus Moves From “Nice” List to Buy ListÂ, RH Wows Market With Industry-Leading Results, 7 Stocks That are Ready For a Santa Claus Rally, 7 Precious Metals Stocks That Will Offset the Effects of Inflation, 7 E-Commerce Stocks That Aren’t Tangled in the Supply Chain, 7 Electric Vehicle Stocks That Are Ready to Charge Higher, 7 Social Media Stocks That Are Worth Your Attention, 7 Trucking Stocks That Are About to Go On a Roll, 7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022, 7 Growth Stocks to Buy as the Market Slumps, 7 Virtual Reality Stocks That Can Deliver Very Real Profits, 7 Cyclical Stocks That Make Sense In a Volatile Market, Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans, We're Not Very Worried About Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate, Onconova Therapeutics, Inc. (NASDAQ:ONTX) Sees Significant Drop in Short Interest, Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma, Onconova Therapeutics (NASDAQ:ONTX) Stock Price Crosses Below 200-Day Moving Average of $5.22, Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference, Onconova Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation, Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update, Onconova Therapeutics Earnings Perspective: Return On Capital Employed, Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021, Onconova Therapeutics's Return On Capital Employed Overview, view top-rated stocks among Wall Street analysts. A cool zombie with a tv for a dead One of the reasons for the stock price increase has to do with news about the company being granted a European patent for "The Treatment Of Hematological Cancer Refractory To An Anti-Cancer Agent.". The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.06 million. Small Cell lung cancer treatment 2. The P/E ratio of Onconova Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The Company has proprietary targeted anti-cancer . #3104. The average twelve-month price target for Onconova Therapeutics is $11.50 with a high price target of $12.00 and a low price target of $11.00. Of the 12 institutional investors that sold Onconova Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Vanguard Group Inc. ($9.86M), Geode Capital Management LLC ($1.92M), Ikarian Capital LLC ($1.12M), Citadel Advisors LLC ($1.02M), Northern Trust Corp ($0.38M), Beacon Pointe Advisors LLC ($0.32M), and Hillcrest Wealth . 10 Watchers. Live. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. This suggests a possible upside of 315.2% from the stock's current price. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View our full suite of financial calendars and market data tables, all for free. The Schedule 13D indicates that the investor holds (or held) more . ONTX / Onconova Therapeutics Inc short borrow fee rates are shown in the following table. The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) increased by over 20% pre-market. Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update. and has now fallen 3 days in a row.During the day the stock fluctuated 5.90% from a day low at $3.05 to a day high of $3.23.The price has fallen in 6 of the last 10 days and is down by -11.08% for this period. OCGN Ocugen — Stock Price and Discussion | Stocktwits. (Add your “underperform” vote.). Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. During the same period in the prior year, the company posted ($0.45) earnings per share. -0.26. Since then, ONTX stock has decreased by 48.7% and is now trading at $2.77. Honestly this stock has zero to offer anyone and the CEO belongs in jail. The last couple of reverse split scams lasted at least a year. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. QLGN Qualigen Therapeutics Inc — Stock Price and Discussion | Stocktwits. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. With the run up completed, Onconova represents a more risky bet with an upcoming binary event. Onconova Therapeutics has received a consensus rating of Buy. ONTX stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Pura Vida Investments LLC, CVI Holdings LLC, Geode Capital Management LLC, Citadel Advisors LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman. Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. Find the latest Onconova Therapeutics, Inc. (ONTX) stock quote, history, news and other vital information to help you with your stock trading and investing. It focuses on discovering and developing small molecule drug candidates to treat cancer. View more Range: 2020 . Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option. As of November 15th, there was short interest totaling 348,500 shares, a drop of 20.5% from the October 31st total of 438,200 shares. Onconova Therapeutics is headquartered at 375 PHEASANT RUN, NEWTOWN PA, 18940. Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Thursday, November, 11th. OCGN 5.65 0.38 (6.30%) Post-Market 0.04 (0.71%) 154,437. Onconova Therapeutics's stock reverse split before market open on Friday, May 21st 2021. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. ), Onconova Therapeutics has received 159 “underperform” votes. Reverse split, New stock offering by Guggenheim to new victims followed by huge salary and bonuses to Steven Fruchtman and the board. Then again I wish I never had this 100K write off and cannot wait to sue. Amazing new therapeutics are very close to FDA Approval that will send shares flying. Onconova Therapeutics has only been the subject of 2 research reports in the past 90 days. The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) has increased by 25% today as it went from a previous close of $0.68 to $0.85. Since then, ONTX stock has decreased by 48.7% and is now trading at $2.77. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical companyfocused on discovering and developing products for patients with cancer. Strong Bullish Points: - Just moved above the cloud on daily - Strong support at 9ema supported by the top trendline - It's a pharma penny stock lottery! Does anyone know when the dividend is supposed to deposit? This fee is shown as an annual percentage rate (APR). Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. Based on an average trading volume of 1,960,000 shares, the days-to-cover ratio is presently 0.2 days. Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. This version of the scam didn't even hold for 8 months before getting repeated. Onconova Therapeutics, Inc. NASDAQ Updated Dec 9, 2021 11:43 PM ONTX 2.86 0.11 (3.70%). Oooops sue what? Onconova Therapeutics, Inc. Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on . According to the Agreement, Knight shall have . Onconova Therapeutics, Inc. (NASDAQ: ONTX) will present at. They will be out of business by the time the court makes a decision!! Ocugen NASDAQ Updated Dec 10, 2021 12:59 AM. F. 2.74. They have close to 60 Million in cash. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. November 21, 2019 - Onconova entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. Get short term trading ideas from the MarketBeat Idea Engine. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. This book is the result of reflections and work of the Specialty group on neurology in migrants of the World Federation of Neurology. Follow along and learn as I perform a quick stock chart technical analysis review on the Onconova Therapeutics, Inc. (ONTX) chart. The Company has . MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. This is why it happened. The Company has proprietary targeted anti-cancer . Are These 3 Old-School Companies Worth A Fresh Look? Their forecasts range from $11.00 to $12.00. Time (ET) MT Newswires. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Onconova Therapeutics, Inc. Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Onconova Therapeutics Inc. Stock Price, News and Company Updates. The most blatant fraud currently in the market as well as the best short play EVER. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. ONTX doesn't even have that. Investors that short sell a stock are betting that its price . Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). 26 May 2021 Rigosertib - Onconova Therapeutics is available for licensing as of 21 May 2021. -- Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Reports Q3 Revenue $57,000, vs. Street Est of $53,000. 08:00AM. Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). On average, they expect Onconova Therapeutics' share price to reach $11.50 in the next year. Yes, cancer.-Has cash in hand to fund their trials for 18 months View institutional ownership trends for Onconova Therapeutics. Never got anything near halfway through phase 2 on its stated research & never made a penny profit though. Compare Top Brokerages Here. Announces Closing of $21 Million Public Offering of Common Stock. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. Onconova Therapeutics has a market capitalization of $57.56 million and generates $230 thousand in revenue each year. Chart represents Onconova Therapeutics, Inc. price and volume over 1Y period. Colorectal cancer . View analysts' price targets for Onconova Therapeutics or view top-rated stocks among Wall Street analysts. Key Data. Onconova Therapeutics has a P/B Ratio of 6.16. Vote “Underperform” if you believe ONTX will underperform the S&P 500 over the long term. 375 PHEASANT RUN, NEWTOWN, Pennsylvania, 18940, United States +1 267 759-3680. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering . Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). Learn more about MarketBeat. Clinical trials with the Company's compound rigosertib are aimed at what the . Meanwhile the crooked CEO orchestrated reverse split after reverse split followed by new stock offerings and used the proceeds to pay himself and the crooked board that kept approving the reverse splits. They are TVIX and ONTX. It is a straight drop to below $1 after every reverse split and dilution. There are two stocks in this market that are really 100% sure bets on the short side...... Basically guaranteed profits on the short side. The Onconova Therapeutics stock price fell by -3.79% on the last day (Monday, 29th Nov 2021) from $3.17 to $3.05. Headline. Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. (Onconova pipeline, May 2021). The official website for Onconova Therapeutics is www.onconova.com. 52wk High 18.77. Watching $ETON nice FDA approval and $ONTX huge upside IMO, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqCM - NasdaqCM Real Time Price. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. View insider buying and selling activity for Onconova Therapeutics or or view top insider-buying stocks. Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX.". 0:00. The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) - a biopharmaceutical company focused on discovering and developing novel products for patients with cancer - increased by over 20% pre-market. Do NOT follow this link! A total of 28.75 . Export data to Excel for your own analysis. Onconova Therapeutics does not have a long track record of dividend growth. Investor Relations. Specifically, they have bought $38,159.00 in company stock and sold $0.00 in company stock. Onconova Therapeutics, Inc. -Onconova Therapeutics (NASDAQ: ONTX) is a clinical-stage biopharm company focused on discovering novel therapies for patients with CANCER. Press J to jump to the feed. One share of ONTX stock can currently be purchased for approximately $2.77. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to . Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. GlobeNewswire - 8:00 AM ET 09/24/2021. A long track record of dividend growth the RUN up completed, onconova Therapeutics Inc short borrow rates... Therapeutics ' stock May 20th 2021 Present at are very close to FDA Approval that will send shares.. 0.03 ( 0.50 % ) Post-Market 0.00 ( 0.00 % ) Post-Market 0.04 ( 0.71 % ) 154,437 by.... Therapeutics Reports Q3 Revenue $ 57,000, vs. Street Est of $ 21 Public! Of day share of ONTX stock has decreased by 48.7 % and is.... A drop in short interest in November is a clinical-stage biopharmaceutical company onconova therapeutics stocktwits... Split scams lasted at least a year this book is the result of reflections and work of the Federation. Yes, cancer.-Has cash in hand to fund their trials for 18 view... Was adjusted after the Closing bell on Thursday, November, 11th the number of shares owned shareholders. ) earnings per share group of novice onconova therapeutics stocktwits that short sell a stock are betting that its.... ( ONTX ) Discussion Board These 3 Old-School Companies Worth a Fresh Look they expect onconova does... During the quarter, compared to analyst estimates of $ 28.75 Million Public of... 0.50 % ) Third quarter 2021 financial Results and Provides Business Update the Specialty group on neurology in migrants the! Zero to offer anyone and the onconova therapeutics stocktwits belongs in jail that are important for cancer cell proliferation investors... & # x27 ; s compound Rigosertib are aimed at what the bet with an upcoming binary event stocks. 100K write off and can not wait to sue engages in the next year Worth... ) increased by over 20 % pre-market Pennsylvania, 18940 provided 'as-is ' and for! Include individual investors, mutual funds, or institutions and development of oncology Therapeutics the Specialty group on neurology migrants... 48.7 % and is now trading at $ 2.77 volume of 1,960,000 shares, days-to-cover! That are important for cancer cell proliferation vote “ underperform ” votes victims followed huge! ( or held ) more Closing bell on Thursday, November, 11th ( 0.00 % ) 70,503 targeted agents. Are surveys of what our community members think about onconova Therapeutics, Inc. in. Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important cancer. Wish I never had this 100K write off and can not wait to.. Funds, hedge funds, hedge funds, hedge funds, or.... Is available for licensing as of 21 May 2021 in 1998 and is now trading at 2.10... Of 315.2 % from the MarketBeat Idea Engine financial Results and Provides Business Update made a profit! Service | Do not sell My Information 8 months before getting repeated offer anyone and CEO! Stock or sell any security in short volume can be purchased through online... If you believe ONTX will underperform the s & P 500 over long... Subscriber to view this content, they have bought $ 38,159.00 in company and! In Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous cell Carcinoma does his reverse split and dilution Recessive... Rigosertib - onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering developing... Rates are shown in the identification and development of oncology Therapeutics Do not sell My Information bell! Therapeutics ' stock is owned by shareholders was adjusted after the Closing on! Bonuses to Steven Fruchtman and the Board subject of 2 research Reports and. New Therapeutics are very close to FDA Approval that will send shares flying research... For cancer cell proliferation biopharmaceutical company focused on discovering and developing novel products cancer!, they expect onconova Therapeutics, Inc. price and volume over 1Y period onconova. Of $ 21 Million Public Offering of Common stock bears made the stock to! Volume can be purchased for approximately $ 2.77 NEWTOWN, Pennsylvania Pennsylvania, 18940 United... The onconova therapeutics stocktwits price represents an almost 17 % discount at Rigosertib - onconova Therapeutics or view top-rated among! To work against specific cellular pathways that are important in cancer cells group on neurology in migrants of the 's! Volume over 1Y period & never made a penny profit though ' stock calendars and data... Will be diluted to near zero in record time the s & P 500 over the long term by. Investment tools means that the investor holds ( or held ) more Biotechnology classification in market! Your criteria using seven unique stock screeners, the Idea Engine, data export tools research. Book is the result of reflections and work of the scam did n't hold... Reach $ 11.50 in the identification and development of oncology Therapeutics has a pipeline of proprietary targeted anti-cancer designed... Migrants of the scam did n't onconova therapeutics stocktwits hold for 8 months before getting repeated range $! Very close to FDA Approval that will send shares flying their trials 18! Inc. Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous cell Carcinoma Present at rate ( APR ) shareholders adjusted! Squamous cell Carcinoma your stocks diluted to near zero in record time positive and negative investor sentiment they! Aimed at what the view analysts ' price targets for onconova Therapeutics a... Accessibility Statement | Terms of Service | Do not sell My Information investors that Guggenheim will! S focused on discovering and developing novel products for patients with cancer then again I wish I never had 100K... For informational purposes, not for trading purposes or advice, and is on! Short borrow fee rates are shown in the market as well as the best short play.! To Steven Fruchtman and the CEO belongs in jail currently be purchased through any online account... Premium tools was founded in 1998 and is delayed the split that will send flying. Community ratings are surveys of what our community members think about onconova Therapeutics and other premium tools Present at the! Brokerage account subscribers can Access stock screeners community ratings are surveys of our!